| Autor: |
Müller, Gabriel Cardozo, Ferreira, Leonardo Souto, Mesias Campos, Felipe Ernesto, Borges, Marcelo Eduardo, Berg de Almeida, Gabriel, Poloni, Silas, Simon, Lorena Mendes, Bagattini, Ângela Maria, Quarti, Michelle, Felizola Diniz Filho, José Alexandre, Kraenkel, Roberto André, Coutinho, Renato Mendes, Camey, Suzi Alves, Kuchenbecker, Ricardo de Souza, Toscano, Cristiana Maria |
| Zdroj: |
The Lancet Regional Health - Americas; January 2023, Vol. 17 Issue: 1 |
| Abstrakt: |
Developing countries have experienced significant COVID-19 disease burden. With the emergence of new variants, particularly omicron, the disease burden in children has increased. When the first COVID-19 vaccine was approved for use in children aged 5–11 years of age, very few countries recommended vaccination due to limited risk-benefit evidence for vaccination of this population. In Brazil, ranking second in the global COVID-19 death toll, the childhood COVID-19 disease burden increased significantly in early 2022. This prompted a risk-benefit assessment of the introduction and scaling-up of COVID-19 vaccination of children. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
